Quick Answer
Structure Therapeutics Inc. reported Cash And Cash Equivalents At Carrying Value of $799.62 million for the year ending 2025.
- Structure Therapeutics Inc. showed an increase of +371.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Structure Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $126.49 million | Q2 2023: $40.59 million | Q3 2023: $50.64 million | Q1 2024: $97.83 million | Q2 2024: $381.63 million | Q3 2024: $172.13 million | Q1 2025: $152.12 million | Q2 2025: $147.02 million | Q3 2025: $102.91 million.
- Over the full 4 years of available data (2022 to 2025), Structure Therapeutics Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 2,964.7%.
- Historical annual values: Fiscal year 2025: $799.62 million | Fiscal year 2024: $169.51 million | Fiscal year 2023: $129.79 million | Fiscal year 2022: $26.09 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: